# US 8,278,322 B2 · HCV NS3 protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,322 B2
- Document ID: US8278322B2
- Status: Granted
- Kind: B2
- Application number: 11/989,886
- Filed: 2006-07-28
- Published: 2011-02-03
- Granted: 2012-10-02
- Earliest claimed: 2005-08-01
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: M. Katharine Holloway; Nigel J. Liverton; John A. McCauley; Michael T. Rudd; Joseph P. Vacca; Steven W. Ludmerer; David B. Olsen
- Web page: https://patentgrep.com/patent/US8278322B2

## CPC

- C07K 5/0812: {and aromatic or cycloaliphatic}
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
n is 1 or 2;
R1 is CO2R10, CONR10SO2R6, CONR10SO2NR8R9, or tetrazolyl;
R2 is C1-C6 alkyl, C2-C6 alkenyl or C3-C8 cycloalkyl, wherein said alkyl, alkenyl or cycloalkyl is optionally substituted with 1 to 3 halo;
R3 is C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C8)alkyl, aryl(C1-C8)alkyl, or Het, wherein aryl is phenyl or naphthyl and said alkyl, cycloalkyl, or aryl is optionally substituted with 1 to 3 substituents selected from the group consisting of halo, OR10, SR10, N(R10)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, halo(C1-C6 alkoxy), NO2, CN, CF3, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, NHCOOR6, NHCOR6, NHCONHR6, CO2R10, C(O)R10, and CON(R10)2;
Het is a 5- or 6-membered saturated cyclic ring having 1, 2 or 3 heteroatoms selected from N, O and S, wherein said ring is optionally substituted with 1 to 3 substituents selected from the group consisting of halo, OR10, SR10, N(R10)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, halo(C1-C6 alkoxy), NO2, CN, CF3, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, NHCOOR6, NHCOR6, NHCONHR6, CO2R10, C(O)R10, and CON(R10)2;
R4 is H, C1-C8 alkyl, C3-C8 cycloalkyl(C1-C8)alkyl, or aryl(C1-C8)alkyl; wherein aryl is phenyl or naphthyl and said alkyl, cycloalkyl, or aryl is optionally substituted with 1 to 3 substituents selected from the group consisting of halo, OR10, SR10, N(R10)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, halo(C1-C6 alkoxy), NO2, CN, CF3, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, NHCOOR6, NHCOR6, NHCONHR6, CO2R10, C(O)R10, and CON(R10)2;
R5 is H, halo, OH, C1-C6 alkoxy, C1-C6 alkyl, CN, CF3, SR10, SO2(C1-C6 alkyl), C3-C8 cycloalkyl, C3-C8 cycloalkoxy, C1-C6 haloalkyl, N(R7)2, aryl, heteroaryl or heterocyclyl;
wherein aryl is phenyl or naphthyl, heteroaryl is a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and heterocyclyl is a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein said aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkoxy, alkyl or alkoxy is optionally substituted with 1 to 4 substituents selected from the group consisting of halo, OR10, SR10, N(R7)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, halo(C1-C6 alkoxy), C3-C6 cycloalkyl, C3-C6 cycloalkoxy, NO2, CN, CF3, SO2(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, S(O)(C1-C6 alkyl), NHCOOR6, NHCOR6, NHCONHR6, CO2R10, C(O)R10, and CON(R10)2; wherein the 2 adjacent substituents of said cycloalkyl, cycloalkoxy, aryl, heteroaryl or heterocyclyl are optionally taken together to form a 3- to 6-membered cyclic ring containing 0-3 heteroatoms selected from N, O and S;
R6 is C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-5)alkyl, aryl, aryl(C1-C4)alkyl, heteroaryl, heteroaryl(C1-C4 alkyl), heterocyclyl, or heterocyclyl(C1-C8 alkyl), wherein said alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 2 W′ substituents; and wherein each aryl is independently phenyl or naphthyl, each heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and each heterocyclyl is independently a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen;
Y is C(═O), SO2, or C(═N—CN);
Z is C(R10)2, O, or N(R4);
M is C1-C12 alkylene or C2-C12 alkenylene or C2-C12 alkynylene, wherein said alkylene or alkenylene is optionally substituted with 1, 2 or 3 substituents selected from the group consisting of C1-C8 alkyl, C3-C8 cycloalkyl(C1-C8 alkyl), and aryl(C1-C8 alkyl); wherein 2 substituents on adjacent carbon atoms of M are optionally taken together to form a 3- to 6-membered cyclic ring containing 0-3 heteroatoms selected from N, O and S, or 2 substituents on the same carbon atom of M are optionally taken together to form a 3- to 6-membered cyclic ring containing 0-3 heteroatoms selected from N, O and S;
A is C(R11) or N;
when R5 is other than H, R11 is H, C1-C6 alkyl, halo, OR10, SR10, or N(R10)2;
when R5 is H, R11 is H, C1-C6 alkyl, halo, OH, C1-C6 alkoxy, CN, CF3, SR10, SO2(C1-C6 alkyl), C3-C8 cycloalkyl, C3-C8 cycloalkoxy, C1-C6 haloalkyl, N(R7)2, aryl, heteroaryl or heterocyclyl; wherein aryl is phenyl or naphthyl, heteroaryl is a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and heterocyclyl is a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein said aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkoxy, alkyl or alkoxy is optionally substituted with 1 to 4 substituents selected from the group consisting of halo, OR10, SR10, N(R7)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, halo(C1-C6 alkoxy), C3-C6 cycloalkyl, C3-C6 cycloalkoxy, NO2, CN, CF3, SO2(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, S(O)(C1-C6 alkyl), NHCOOR6, NHCOR6, NHCONHR6, CO2R10, C(O)R10, and CON(R10)2; wherein the 2 adjacent substituents of said cycloalkyl, cycloalkoxy, aryl, heteroaryl or heterocyclyl are optionally taken together to form a 3- to 6-membered cyclic ring containing 0-3 heteroatoms selected from N, O and S;
or R5 and R11 are optionally taken together to form a 5- to 6-membered saturated, unsaturated non-aromatic, or aromatic cyclic ring having 0-2 heteroatoms selected from N, O and S;
each R7 is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl(C1-5)alkyl, aryl, aryl(C1-C4)alkyl, heteroaryl, heteroaryl(C1-C4 alkyl), heterocyclyl, or heterocyclyl(C1-C8 alkyl), wherein said alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 2 W′ substituents; and wherein each aryl is independently phenyl or naphthyl, each heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and each heterocyclyl is independently a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen;
each W is independently H, halo, OR7, C1-C6 alkyl, CN, CF3, NO2, SR7, CO2R7, CON(R7)2, C(O)R7, N(R10)C(O)R7, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), C3-C8 cycloalkyl, C3-C8 cycloalkoxy, C1-C6 haloalkyl, N(R7)2, N(C1-C6 alkyl)O(C1-C6 alkyl), halo(C1-C6 alkoxy), NR10SO2R7, SO2N(R7)2, NHCOOR7, NHCONHR7, aryl, heteroaryl or heterocyclyl; wherein aryl is phenyl or naphthyl, heteroaryl is a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and heterocyclyl is a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein 2 adjacent W moieties are optionally taken together with the atoms to which they are attached to form a 5- to 6-membered saturated, unsaturated non-aromatic, or aromatic cyclic ring having 0-2 heteroatoms selected from N, O and S;
each W′ is independently halo, OR10, C1-C6 alkyl, CN, CF3, NO2, SR10, CO2R10, CON(R10)2, C(O)R10, N(R10)C(O)R10, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), C3-C8 cycloalkyl, C3-C8 cycloalkoxy, C1-C6 haloalkyl, N(R10)2, N(C1-C6 alkyl)O(C1-C6 alkyl), halo(C1-C6 alkoxy), NR 10SO2R10,)SO2N(R102, NHCOOR10, NHCONHR10, aryl, heteroaryl or heterocyclyl; wherein aryl is phenyl or naphthyl, heteroaryl is a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and heterocyclyl is a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein 2 adjacent W′ moieties are optionally taken together with the atoms to which they are attached to form a 5- to 6-membered saturated, unsaturated non-aromatic, or aromatic cyclic ring having 0-2 heteroatoms selected from N, O and S;
R8 is C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C8 alkyl), aryl, aryl(C1-C4 alkyl), heteroaryl, heterocyclyl, heteroaryl(C1-C4 alkyl), or heterocyclyl(C1-C8 alkyl), wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with 1 to 4 substituents selected from the group consisting of aryl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, C1-C6 alkyl, halo(C1-C6 alkoxy), halo, OR10, SR10N(R10)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C(O)R10, C1-C6 haloalkyl, NO2, CN, CF3, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, NHCOOR6, NHCOR6, NHCONHR6, CO2R10, and)C(O)N(R102; wherein each aryl is independently phenyl or naphthyl; each heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen;
and each heterocyclyl is independently a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein the 2 adjacent substituents of said cycloalkyl, cycloalkoxy, aryl, heteroaryl or heterocyclyl are optionally taken together to form a 3- to 6-membered cyclic ring containing 0-3 heteroatoms selected from N, O and S;
R9 is C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C8 alkyl), C1-C8 alkoxy, C3-C8 cycloalkoxy, aryl, aryl(C1-C4 alkyl), heteroaryl, heterocyclyl, heteroaryl(C1-C4 alkyl), or heterocyclyl(C1-C8 alkyl), wherein said alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, heteroaryl or heterocyclyl is optionally substituted with 1 to 4 substituents selected from the group consisting of aryl, C3-C8 cycloalkyl, heteroaryl, heterocyclyl, C1-C6 alkyl, halo(C1-C6 alkoxy), halo, OR10, SR10, N(R10)2, N(C1-C6 alkyl)O(C1-C6 alkyl), C1-C6 alkyl, C(O)R10, C1-C6 haloalkyl, NO2, CN, CF3, SO2(C1-C6 alkyl), S(O)(C1-C6 alkyl), NR10SO2R6, SO2N(R6)2, NHCOOR6, NHCOR6, NHCONHR6, CO2R10, and)C(O)N(R10)2;
wherein each aryl is independently phenyl or naphthyl; each heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and each heterocyclyl is independently a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein the 2 adjacent substituents of said cycloalkyl, cycloalkoxy, aryl, heteroaryl or heterocyclyl are optionally taken together to form a 3- to 6-membered cyclic ring containing 0-3 heteroatoms selected from N, O and S;
or R8 and R9 are optionally taken together, with the nitrogen atom to which they are attached, to form a 4- to 8-membered monocyclic ring containing 0-2 additional heteroatoms selected from N, O and S; and
each R10is independently H or C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula III:

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is CO2R10 or CONR10SO2R6.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is CO2H.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R1 is CONHSO2R6.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R6 is C3-C8 cycloalkyl, C1-C8 alkyl, aryl, or aryl(C1-C4)alkyl.

### Claim 7 (depends on 3)

The compound of claim 3, wherein R2 is C1-C4 alkyl or C2-C4 alkenyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R3 is C5-C6 cycloalkyl or C1-C8 alkyl optionally substituted with 1 to 3 halo substituents.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R5 is H, halo, aryl, heteroaryl or N(R7)2.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R5 is H or halo.

### Claim 11 (depends on 9)

The compound of claim 9, wherein R5 is aryl or heteroaryl.

### Claim 12 (depends on 9)

The compound of claim 9, wherein Y is C═O.

### Claim 13 (depends on 12)

The compound of claim 12, wherein Z is O, NH, N(C1-C8 alkyl) or C(R10)2.

### Claim 14 (depends on 13)

The compound of claim 13, wherein M is unsubstituted C4-C7 alkylene or unsubstituted C4-C7 alkenylene.

### Claim 15 (depends on 14)

The compound of claim 14, wherein n is 1 and W is H, C1-C6 alkoxyl, C1-C6 alkyl, OH, halo, N(R7)2 wherein R7 is H or C1-C6 alkyl.

### Claim 16 (depends on 15)

The compound of claim 15, wherein A is N.

### Claim 17 (depends on 15)

The compound of claim 15, wherein A is C(R11) wherein R11 is H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy or halo.

### Claim 18 (depends on 10)

The compound of claim 10, wherein R2 is C2-C4 alkenyl, R5 is H, R6 is C3-C8 cycloalkyl, W is R7 or H, Y is C(═O), Z is O, and n is 1.

### Claim 19 (depends on 18)

The compound of claim 18, wherein M is selected from the group consisting of:

### Claim 20 (depends on 19)

The compound of claim 19, wherein R3 is C5-C6 cycloalkyl or C3-C5 alkyl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein R6 is C3-C5 cycloalkyl.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of compounds III-1 to III-38:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of compounds III-39 to III-187:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

The compound of claim 1, wherein the compound is (1R,2S)-1-({[(2R,4S,7S)-7-tert-Butyl-6,9-dioxo-3 ,4,6,7,8,9,12,13 -octahydro-2H,11H-16,18-ethanediylidene-2,5 -methanopyrido [2,3-k][1,10,3,6]dioxadiazacyclononadecin-4-yl]carbonyl}amino)-2-vinylcyclopropanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, further comprising a second therapeutic agent selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.

### Claim 28 (depends on 1)

A method of inhibiting HCV NS3 protease activity in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound of claim 1.

### Claim 29 (depends on 1)

A method of treating infection by HCV in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound of claim 1.

### Claim 30 (depends on 29)

The method of claim 29, further comprising administering at least one second therapeutic agent selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent.

### Claim 31 (depends on 30)

The method of claim 30, wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.

### Claim 32 (depends on 1)

A compound of claim 1, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

A pharmaceutical composition comprising an effective amount of the compound of claim 32 and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, further comprising a second therapeutic agent selected from a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.

### Claim 35 (depends on 32)

A method of inhibiting HCV NS3 protease activity and/or treating infection by HCV in a subject in need thereof, said method comprising administering to said subject an effective amount of the compound of claim 32.

### Claim 36 (depends on 35)

The method of claim 35, wherein said method further comprises administering at least one second therapeutic agent selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent.

### Claim 37 (depends on 36)

The method of claim 36, wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.

### Claim 38

A compound of formula III-131:
or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 38)

A pharmaceutical composition comprising an effective amount of the compound of claim 38 and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 38)

A method of inhibiting HCV NS3 protease activity and/or treating infection by HCV in a subject in need thereof, said method comprising administering to said subject an effective amount of the compound of claim 38.
